Impact Factor
4.11
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.11
2,704 total citations
h5-index
48
h5 depth signal
Cited share
78.7%
440 of 559
Total citations
2,704
Citation footprint
Metric signal
6.32
External metric anchor
Self-citation
2.7%
72 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,281
China
266
Japan
163
United Kingdom
161
Germany
142
Citing Fields of Research
Pharmacology & Toxicology
520
Cancer Drugs
277
Medical Ethics
264
Cardiology
187
Oncology
184
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,067
Articles tracked across the journal lifetime
Indexed publication set
559
440 cited publications
Last 12 months
379
31.6 publications/month
Open access share
100.0%
379 OA publications in the last year
Leading citing country
United States
1,281 citing publications
Leading citing field
Pharmacology & Toxicology
520 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 2008-
v1n1, 2008- ; Selected citations only
Active Coverage
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
Medical Ethics
Cancer Drugs
Cardiology
Oncology
Genetics & Genomics
Broad Categories
Medicine
Medical Ethics
Cardiology
Genetics & Genomics
Pharmacology & Toxicology
Hematology
Cancer Drugs
MeSH Descriptors
Biomedical Research
Clinical Medicine
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/cts.70748
Open DOI
A Phase 1 Study of MK ‐1942, a Negative Allosteric Modulator of mGluR2 , in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype
MK‐1942 is a negative allosteric modulator of the metabotropic glutamate receptor 2 that was investigated for the treatment of Alzheimer's disease and depression. Nonclinical studies with recombinant human CYPs and genotyped human hepato...
02
DOI 10.1111/cts.70744
Open DOI
A Systematic Intracranial Exposure‐Response Evaluation of Brain‐Penetrant Inhibitors: Informing Dose Selection for Brain Metastases
Brain metastases (BMs) represent a major clinical challenge due to their high incidence in cancers such as non‐small cell lung cancer (NSCLC) and breast cancer, and the limited efficacy of systemic therapies resulting from inadequate dru...
03
DOI 10.1111/cts.13848
Open DOI
Issue Information
04
DOI 10.1111/cts.70745
Open DOI
PHARMWATCH : A Proposed Multilayer Pharmacogenomics Framework for Contextual Star Allele Interpretation
The Clinical Pharmacogenetics Implementation Consortium (CPIC) bases its drug‐gene recommendations on the assignment of star alleles, which map known genotypes to defined functional categories and corresponding drug dosage guidelines. Th...
05
DOI 10.1111/cts.70742
Open DOI
Clinical Decision Support Models to Optimize Controlled Ovarian Hyperstimulation: A Scoping Review
Controlled ovarian hyperstimulation (COH) is a precision medicine challenge, with substantial inter‐individual variability in ovarian response affecting treatment efficacy and safety during in vitro fertilization (IVF). Clinical decision...
06
DOI 10.1111/cts.70720
Open DOI
Analysis of Virologic and Clinical Predictors for Hospitalization, Supported by Machine Learning, in a Phase 3 Molnupiravir COVID ‐19 Treatment Trial
Machine learning (ML) is increasingly being used in clinical medicine. The objective of this study was to identify factors predictive of hospitalization, with the support of ML, in outpatients with mild‐to‐moderate COVID‐19. Unvaccinated...
07
DOI 10.1111/cts.70746
Open DOI
Translational Prediction of Hemodialysis Clearance Integrating Molecular Structure and Dialysis Conditions
Quantitative prediction of drug removal by hemodialysis is essential for rational dose design in patients with renal failure. We aimed to develop a machine learning‐based quantitative structure–pharmacokinetic relationship (QSPKR) model ...
08
DOI 10.1111/cts.70737
Open DOI
Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack‐Free Probability and Quality of Life Over 5 Years
Hereditary angioedema (HAE) attacks are recurrent, debilitating, and potentially life‐threatening. Across the clinical program, garadacimab long‐term prophylaxis demonstrated early onset and durable, sustained protection against HAE atta...
09
DOI 10.1111/cts.70738
Open DOI
Population Pharmacokinetics of Cabozantinib: Updated Analyses Including Data in Combination With Atezolizumab in Patients With Castration‐Resistant Prostate Cancer and Other Tumor Types
Cabozantinib is a small‐molecule tyrosine kinase inhibitor approved for the treatment of various locally advanced or metastatic solid tumors. The phase 1b COSMIC‐021 study evaluated cabozantinib as a monotherapy or in combination with at...
10
DOI 10.1111/cts.70741
Open DOI
Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease
Sjögren's disease (SD) is an autoimmune condition characterized by chronic inflammation and impaired secretory function of the salivary glands (SG). The proresolving lipid mediator AT‐RvD1 restores SG function in SD‐like mice; however, i...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 4 (2011)
Also issued online.